Post
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NN-9931?
NN-9931 is a recombinant peptide commercialized by Novo Nordisk, with a leading Phase III program in Metabolic Dysfunction-Associated Steatohepatitis (MASH). …
Risk adjusted net present value: What is the current valuation of Enliven Therapeutics’s ELVN-002?
ELVN-002 is a small molecule commercialized by Enliven Therapeutics, with a leading Phase I program in Human Epidermal Growth Factor …
Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07275315?
PF-07275315 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema). According …
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s LY-3972406?
LY-3972406 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis …
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NNC0519-0130?
NNC0519-0130 is commercialized by Novo Nordisk, with a leading Phase II program in Type 2 Diabetes. According to Globaldata, …
Risk adjusted net present value: What is the current valuation of Novartis’s XXB-750?
XXB-750 is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Systolic Heart Failure. According to …
Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-9574?
AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer. According to Globaldata, …
Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?
MK-1084 is a small molecule commercialized by Merck, with a leading Phase I program in Metastatic Colorectal Cancer. According to …
Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-400?
ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer. According …
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sabestomig?
Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma. According …
Risk adjusted net present value: What is the current valuation of Sanofi’s SAR-441566?
SAR-441566 is a small molecule commercialized by Sanofi, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris). According …
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Olomorasib?
Olomorasib is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Non-Small Cell …
Risk adjusted net present value: What is the current valuation of Turnstone Biologics’s TIDAL-01?
TIDAL-01 is a cell therapy commercialized by Turnstone Biologics, with a leading Phase I program in Human Epidermal Growth Factor …
Risk adjusted net present value: What is the current valuation of AstraZeneca’s CMG-901?
CMG-901 is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Adenocarcinoma Of The Gastroesophageal …
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NN-1845?
NN-1845 is a recombinant protein commercialized by Novo Nordisk, with a leading Phase I program in Type 1 Diabetes (Juvenile …